	US 12,436,146 B2
	Cell-based assay for quantifying the potency and efficacy of cannabinoids and/or terpenoids, and methods of use thereof
Harold C. Smith, Rochester, NY (US)
Assigned to CannaMetrix, LLC, Rochester, NY (US)
Filed by CannaMetrix, LLC, Rochester, NY (US)
Filed on Oct. 9, 2023, as Appl. No. 18/378,011.
Application 18/378,011 is a continuation of application No. 16/648,057, granted, now 11,782,050, previously published as PCT/US2018/051569, filed on Sep. 18, 2018.
Claims priority of provisional application 62/560,646, filed on Sep. 19, 2017.
Prior Publication US 2024/0295543 A1, Sep. 5, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. G01N 33/50 (2006.01); C12N 9/22 (2006.01); C12N 15/113 (2010.01); G01N 33/94 (2006.01)

CPC G01N 33/5008 (2013.01) [C12N 9/22 (2013.01); C12N 15/113 (2013.01); G01N 33/5044 (2013.01); G01N 33/5067 (2013.01); G01N 33/94 (2013.01); C12N 2310/20 (2017.05); C12N 2800/80 (2013.01)]

21 Claims

1. A cell-based assay for quantifying the potency and/or efficacy of one or more cannabinoids and/or terpenoids present in a test sample, wherein the assay comprises:

(a) one or more human cell types derived from one or more different human tissues, wherein:

(i) the one or more human cell types have either wild-type CB1 and/or CB2, CB1 knockouts, CB2 knockouts, or CB1/CB2 knockouts, and

(ii) the one or more human cell types are genetically engineered to express a G protein selected from a promiscuous G alpha protein that converts G protein-coupled receptor (GPCR) signaling to a positive calcium release and/or other changes; and

(b) one or more reagents for quantifying the potency and/or efficacy of the one or more cannabinoids and/or terpenoids present in the test sample, wherein the quantifying is based on measuring GPCR-dependent changes in the one or more human cell types after the test sample is contacted with the one or more human cell types compared with a calibration control.